Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diffusion Pharmaceuticals Inc DFFN

Healthcare Biotechnology
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine... see more

Recent & Breaking News (NDAQ:DFFN)

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

GlobeNewswire May 4, 2022

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

GlobeNewswire April 18, 2022

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

GlobeNewswire April 11, 2022

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

GlobeNewswire April 8, 2022

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

GlobeNewswire March 21, 2022

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

GlobeNewswire February 24, 2022

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during "J.P. Morgan Week 2022"

GlobeNewswire December 20, 2021

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

GlobeNewswire December 16, 2021

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

GlobeNewswire December 1, 2021

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

GlobeNewswire November 22, 2021

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 10, 2021

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

GlobeNewswire October 28, 2021

Diffusion Pharmaceuticals Issues Letter to Shareholders

GlobeNewswire September 9, 2021

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

GlobeNewswire September 8, 2021

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division

GlobeNewswire August 30, 2021

Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire September 5, 2017

Diffusion Pharmaceuticals Names William Hornung Chief Business Officer

GlobeNewswire August 23, 2017

Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire August 14, 2017

Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer

GlobeNewswire July 31, 2017

Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer

GlobeNewswire July 20, 2017